Clear All
754 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9301 Obinutuzumab Gazyva 10 mg Immunotherapy Monoclonal Antibody CD20 No 2013 Jan 1, 2015 In Use
J9023 Avelumab Bavencio 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Jan 1, 2018 In Use
C9483 Atezolizumab Tecentriq 10 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2016 Oct 1, 2016 In Use
J3263 Toripalimab-tpzi Loqtorzi 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2023 Jun 10, 2024 In Use
J0202 Alemtuzumab Lemtrada 1 mg Immunotherapy Monoclonal Antibody CD52 No 2001 Jan 1, 2016 In Use
Not yet assigned Tisagenlecleucel Kymriah consult labeling Immunotherapy CAR-T CD19 No 2017 In Use
J9015 Aldesleukin Proleukin Per single vial (1 vial = 22 million IU) Immunotherapy Cytokine Interleukin-2 No 1992 Oct 1, 1996 In Use
J9382 Zenocutuzumab-zbco Bizengri 1mg Immunotherapy Bispecific Antibody HER2, HER3 No 2024 May 13, 2025 In Use
C9214 Bevacizumab Avastin 10 mg Immunotherapy Monoclonal Antibody VEGFR No 2004 Feb 26, 2004 Dec 31, 2004 No Longer Used
J9216 Interferon Gamma-1b Actimmune 3 million units Immunotherapy Cytokine Interferon No 1999 Jan 1, 2009 In Use
J9311 Rituximab and Hyaluronidase Rituxan Hycela 10mg Immunotherapy Monoclonal Antibody CD20 No 2017 Jan 1, 2019 In Use
J1323 Elranatamab-bcmm Elranatamab-bcmm 1mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2023 Apr 17, 2024 In Use
C9491 Avelumab Bavencio 10 mg Immunotherapy Checkpoint Inhibitor PD-1 No 2017 Oct 1, 2017 In Use
Q2058 Obecabtagene autoleucel AUCATZYL up to 400 million Immunotherapy CAR-T CD-19 No 2024 May 13, 2025 In Use
C9131 Ado-Trastuzumab Emtansine Kadcyla 1mg Immunotherapy Drug Antibody Conjugate HER2 No 2013 Jul 1, 2013 Dec 31, 2013 No Longer Used
Q9979 Alemtuzumab Lemtrada 1 mg Immunotherapy Monoclonal Antibody CD52 No 2001 Oct 1, 2015 Dec 31, 2015 No Longer Used
Q5126 Bevacizumab-maly Alymsys 10mg Immunotherapy Monoclonal Antibody VEGF No 2022 Nov 28, 2022 In Use
J9173 Durvalumab Imfinzi 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2017 Jan 1, 2019 In Use
C9416 BCG BCG, Intravesical Per instillation Immunotherapy Biological Response Modifier Live Vaccine No 1990 Jan 1, 2004 Dec 31, 2003 No Longer Used
J9359 Loncastuximab tesirine-lpyl Zynlonta 0.075mg Immunotherapy Drug Antibody Conjugate CD19 No 2021 Mar 25, 2022 In Use
J9285 Olaratumab Lartruvo 10 mg Immunotherapy Monoclonal Antibody PDGFR No 2016 Apr 1, 2017 In Use
J1326 Zolbetuximab-clzb Vyloy 2mg Immunotherapy Monoclonal Antibody CLDN18.2 No 2024 May 13, 2025 In Use
C9118 Ibritumomab tiuxetan Zevalin Per MCI Immunotherapy Radioimmunotherapy CD20 No 2002 Oct 1, 2002 Dec 31, 2002 No Longer Used
Q5114 Trastuzumab-dkst Ogivri 10mg Immunotherapy Monoclonal Antibody HER2 No 2017 Jul 1, 2019 In Use
J9349 Tafasitamab-cxix MONJUVI 2mg Immunotherapy Monoclonal Antibody CD19 No 2020 Apr 1, 2021 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.